GB1350160A - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB1350160A
GB1350160A GB149572A GB149572A GB1350160A GB 1350160 A GB1350160 A GB 1350160A GB 149572 A GB149572 A GB 149572A GB 149572 A GB149572 A GB 149572A GB 1350160 A GB1350160 A GB 1350160A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
acid
weight
parts
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB149572A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foremost Mckesson Inc
Original Assignee
Foremost Mckesson Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foremost Mckesson Inc filed Critical Foremost Mckesson Inc
Publication of GB1350160A publication Critical patent/GB1350160A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1350160 Pharmaceutical compositions FOREMOST-McKESSON Inc 12 Jan 1972 [29 June 1971 26 Nov 1971] 1495/72 Heading A5B Pharmaceutical compositions for the treatment of atherosclerosis and psoriasis and for reducing elevated serum uric acid levels associated with hyperuricemia and/or gout consist solely of a mixture of from 20 to 80 parts by weight of ascorbic acid or non-toxic water-soluble salt thereof together with from 80 to 20 parts by weight of folic acid, folinic acid or 6-formyl pteridine or a water-soluble non-toxic salt thereof together with a pharmaceutically acceptable carrier or extender. The composi tions may be administered orally or parenterally in the form of tablets, capsules or suspensions.
GB149572A 1971-06-29 1972-01-12 Pharmaceutical compositions Expired GB1350160A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15811871A 1971-06-29 1971-06-29
US20257671A 1971-11-26 1971-11-26

Publications (1)

Publication Number Publication Date
GB1350160A true GB1350160A (en) 1974-04-18

Family

ID=26854750

Family Applications (1)

Application Number Title Priority Date Filing Date
GB149572A Expired GB1350160A (en) 1971-06-29 1972-01-12 Pharmaceutical compositions

Country Status (3)

Country Link
DE (1) DE2231989A1 (en)
FR (1) FR2143641B1 (en)
GB (1) GB1350160A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0898965A2 (en) * 1997-06-13 1999-03-03 EPROVA Aktiengesellschaft Use of tetrahydrofolates for modulating the homocysteine level
CN114344328A (en) * 2020-10-12 2022-04-15 深圳奥萨制药有限公司 Composition for reducing risk of gout of hypertension patient

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0898965A2 (en) * 1997-06-13 1999-03-03 EPROVA Aktiengesellschaft Use of tetrahydrofolates for modulating the homocysteine level
EP0898965A3 (en) * 1997-06-13 2000-11-15 EPROVA Aktiengesellschaft Use of tetrahydrofolates for modulating the homocysteine level
EP1685840A2 (en) * 1997-06-13 2006-08-02 Merck Eprova AG Use of tetrahydrofolates for modulating the homocysteine level
EP1685840A3 (en) * 1997-06-13 2010-06-02 Merck Eprova AG Use of tetrahydrofolates for modulating the homocysteine level
CN114344328A (en) * 2020-10-12 2022-04-15 深圳奥萨制药有限公司 Composition for reducing risk of gout of hypertension patient
CN114344328B (en) * 2020-10-12 2024-01-16 深圳奥萨制药有限公司 Composition for reducing gout occurrence risk of hypertensive patient

Also Published As

Publication number Publication date
FR2143641B1 (en) 1975-12-26
DE2231989A1 (en) 1973-01-18
FR2143641A1 (en) 1973-02-09

Similar Documents

Publication Publication Date Title
CA983030A (en) 2-(substituted pyrrolidino)-8-lower alkyl-5,8-dihydro-5-oxopyrido(2,3-d) pyrimidine-6-carboxylic acid derivatives, and process for the preparation of the same
AU4436872A (en) 2,3-DIHYDRO-OXOIMIDAZO [1,2-a] PYRIMIDINES, THEIR ACID ADDITION SALTS THEREOF AND PROCESSES FOR THEIR PREPARATION
GB1350160A (en) Pharmaceutical compositions
ES419506A1 (en) {8 1-Oxo-2,3-hydrocarbylene-5-indanyloxy(or thio){9 alkanoic acids
IE38641B1 (en) New pyrazolodiazepine compounds and methods for their production
GB1191246A (en) Vitamin-containing Preparations
ES399906A1 (en) Process for the production of dyestuff preparations
GB1210968A (en) Improvements in or relating to the treatment of gastric ailments
GB1446584A (en) Agent for deodorising and influencing perspiration
GB1245316A (en) Novel quinazolinone derivative and process for production thereof
IE34648B1 (en) Pharmaceutical compositions and a process for the manufacture thereof
IE39049B1 (en) New 1,4-dihydroquinoline derivatives their production and their medicinal use
GB1118606A (en) Compositions for the treatment of haemorrhoids
IE34590L (en) Phenylethanolamine derivatives
GB1164135A (en) Pharmaceutical Compositions Comprising Methdilazine Sulphoxide
IE35711L (en) Pharmaceutical compositions
GB1501839A (en) Pharmaceutical compositions for the inhibition of thrombocyte aggregation
GB1283505A (en) Substituted alkanol-thioalkyl-amines
IE33519B1 (en) Novel benzyl-hydrazide derivatives and a process for the manufacture thereof and novel benzylidene-hydrazide derivatives useful in said process
ES481296A1 (en) Ester derivatives of quinolopyran-4-one-2-carboxylic acids and antiallergic antasthmatics
GB1509778A (en) Pharmaceutical composition and dosage units thereof
GB1289039A (en)
GB1440849A (en) Cerebral vasodilator compositions
GB1227646A (en)
FUKUSHIMA My Polysaccharide Therapy of Haman Cancer and the Study on Polysaccharide by Hamashima et al

Legal Events

Date Code Title Description
PS Patent sealed
PLE Entries relating assignments, transmissions, licences in the register of patents
PCNP Patent ceased through non-payment of renewal fee